

PTO/SB/17 (01-08)  
Approved for use through 7/31/2005. OMB 0561-0032  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no person are required to respond to a collection of information unless it displays a valid OMB control number.

**FEE TRANSMITTAL**  
For FY 2006

☒ Applicant claims small entity status. See 37 CFR 1.27

**TOTAL AMOUNT OF PAYMENT** (\$) 180.00

**METHOD OF PAYMENT** (check all that apply)

☐ Check ☐ Credit Card ☐ Money Order ☐ None ☐ Other (please identify):

☒ Deposit Account Deposit Account Number: 22-0185 Deposit Account Name: Connolly Bove Lodge & Hutz LLP

For the above-identified deposit account, the Director is hereby authorized to: (check all that apply)

☒ Charge fee(s) indicated below ☐ Charge fee(s) indicated below, except for the filing fee

☒ Charge any additional fee(s) or underpayment of fee(s) under 37 CFR 1.16 and 1.17 ☒ Credit any overpayments

**FEE CALCULATION (All the fees below are due upon filing or may be subject to a surcharge.)**

**1. BASIC FILING, SEARCH, AND EXAMINATION FEES**

Application Type	FILING FEES		SEARCH FEES		EXAMINATION FEES		Fees Paid (\$)
	Fee (\$)	Small Entity Fee (\$)	Fee (\$)	Small Entity Fee (\$)	Fee (\$)	Small Entity Fee (\$)	
Utility	300	150	500	250	200	100	
Design	200	100	100	50	130	65	
Plant	200	100	300	150	160	80	
Reissue	300	150	500	250	600	300	
Provisional	200	100	0	0	0	0	

**2. EXCESS CLAIM FEES**

Fee Description

Each claim over 20 (including Reissues)

Each independent claim over 3 (including Reissues)

Multiple dependent claims

Total Claims	Extra Claims	Fee (\$)	Fee Paid (\$)
- 20 =	x		

HP = highest number of total claims paid for, if greater than 20.

Indep. Claims	Extra Claims	Fee (\$)	Fee Paid (\$)
- 3 =	x		

HP = highest number of independent claims paid for, if greater than 3.

**3. APPLICATION SIZE FEE**

If the specification and drawings exceed 100 sheets of paper (excluding electronically filed sequence or computer listings under 37 CFR 1.52(e)), the application size fee due is \$250 (\$125 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).


Total Sheets	Extra Sheets	Number of each additional 50 or fraction thereof	Fee (\$)	Fee Paid (\$)
- 100 =	150	(round up to a whole number) x		

**4. OTHER FEE(S)**

Non-English Specification, \$130 fee (no small entity discount)

Other (e.g., late filing surcharge): 1806 Submission of an Information Disclosure Statement 180.00

**SUBMITTED BY**

Signature: 

Name (Print/Type): Burton A. Amernick

Registration No. (Attorney/Agent): 24,852

Telephone: (202) 331-7111

Date: August 31, 2006

RECEIVED  
CENTRAL FAX CENTER

AUG 31 2006

**FAX TRANSMISSION****RECEIVED**  
**CENTRAL FAX CENTER****AUG 31 2006****DATE:** August 31, 2006**PTO IDENTIFIER:** Application Number 09/713,512-Conf. #4513  
Patent Number**Inventor:** Christine L. O'Day et al.**MESSAGE TO:** US Patent and Trademark Office**FAX NUMBER:** (571) 273-8300**FROM:** CONNOLLY BOVE LODGE & HUTZ LLP  
Burton A. Amernick**PHONE:** (202) 331-7111**Attorney Dkt. #:** 22116-00005-US5**PAGES (Including Cover Sheet):** 28**CONTENTS:** Fee Transmittal (1 page)  
Information Disclosure Statement (2 pages)  
IDS (Citation) by Applicant (3 Reference) (1 page)  
Cited Ref (22 pages)  
Charge \$180.00 to deposit account 22-0185  
Certificate of Transmission (1 page)

If your receipt of this transmission is in error, please notify this firm immediately by collect call to sender at (202) 331-7111 and send the original transmission to us by return mail at the address below.

This transmission is intended for the sole use of the individual and entity to whom it is addressed, and may contain information that is privileged, confidential and exempt from disclosure under applicable law. You are hereby notified that any dissemination, distribution or duplication of this transmission by someone other than the intended addressee or its designated agent is strictly prohibited.

**CONNOLLY BOVE LODGE & HUTZ LLP**  
1990 M Street, N.W., Suite 800, Washington, DC 20036  
Telephone: (202) 331-7111 Facsimile:

PTO/SB/97 (09-04)  
Approved for use through 07/31/2006. OMB 0651-0031  
U. S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Application No. (if known): 09/713,512

Attorney Docket No.: 22116-00005-US5

RECEIVED  
CENTRAL FAX CENTER

AUG 31 2006

**Certificate of Transmission under 37 CFR 1.8**

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office.

on 8/31/06  
Date



Signature

Nicole Brown

Typed or printed name of person signing Certificate

Registration Number, if applicable

Telephone Number

Note: Each paper must have its own certificate of transmission, or this certificate must identify each submitted paper.

Fee Transmittal (1 page)  
Information Disclosure Statement (2 pages)  
IDS (Citation) by Applicant (1 Reference) (1 page)  
Cited Ref (11 pages)

Docket No.: 22116-00005-US5  
(PATENT)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of:  
Christine L. O'Day et al.

Application No.: 09/713,512

Filed: November 14, 2000

For: NOVEL POLYAMINE ANALOGUES AS  
THERAPEUTIC AND DIAGNOSTIC  
AGENTS

Confirmation No.: 4513

Art Unit: 1621

Examiner: R. A. Keys

**RECEIVED**  
**CENTRAL FAX CENTER**

**AUG 31 2006**

**INFORMATION DISCLOSURE STATEMENT (IDS)**

MS Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the reference listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the reference be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed after the mailing date of a Final Office Action or Notice of Allowance, whichever occurred first, but on or before payment of the Issue Fee (37 CFR 1.97(d)). Applicant(s) hereby petition(s) that the Information Disclosure Statement be considered.

Citation BA was first cited in a corresponding Canadian application not more than three months prior to the filing of this Information Disclosure Statement. Citation CA was cited in the prior IDS as Citation CC1, but a copy of this Citation was inadvertently omitted. A copy of

484075

Application No.: 09/713,512

Docket No.: 22116-00005-US5

Citation CB was filed along with our prior IDS, but it was inadvertently not cited in the PTO/SB/08a/b (07-05) Information Disclosure Statement By Applicant Form. Accordingly, Citations CA and CB should also be considered pursuant to 37 CFR 1.97(f), since it is clear that a bona fide was made with respect to the prior Information Disclosure Statement filed on March 1, 2006 and it is clear that the above omission were inadvertent.

Applicant submits herewith a copy of the foreign patent and of the publications in accordance with 37 CFR 1.98(a)(2).

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed reference.

Please charge \$180.00 and any additional fees associated with this paper to our Deposit Account No. 22-0185, under Order No. 22116-00005-US5.

Dated: 8-31-06

Respectfully submitted,

By

Burton A. Amernick

Registration No.: 24,852

CONNOLLY BOVE LODGE &amp; HUTZ LLP

1990 M Street, N.W., Suite 800

Washington, DC 20036

(202) 331-7111 (Phone)

(202) 293-6229 (Fax)

Attorney for Applicant

PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0851-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO		Complete if Known	
		Application Number	09/713,512-Conf. #4513
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use as many sheets as necessary)		Filing Date	November 14, 2000
		First Named Inventor	Christine L. O'Day
		Art Unit	1621
		Examiner Name	R. A. Keys
Sheet 1 of 1		Attorney Docket Number	22116-00005-US5

 RECEIVED  
 CENTRAL FAX CENTER  
 AUG 31 2006

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> -Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>4</sup>
	BA	JP-2-268658-A	10-17-1990	Nakajima Terumi		✓

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 801.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>2</sup>
	CA	"The role of polyamine catabolism in polyamine analogue-induced programmed cell death," Ha et al., <i>Proc. Natl. Acad. Sci.</i> , Vol. 94, pages 11557-11562, October 1997.		
	CB	"The natural polyamine spermine functions directly as a free radical scavenger", Ha et al., <i>Proc. Natl. Acad. Sci.</i> Vol. 95, pages 11140-11145, September 1998.		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--